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Globally, in 2010, there were an estimated 15.5 million opioid-
dependent people, with opiate use disorder accounting for 9 million 
disability-adjusted life-years. North America, Eastern Europe and 
southern sub-Saharan Africa are among the countries most adversely 
affected.[1] The growing recognition of opioid misuse, especially of 
injectable opioids, has resulted in the need for effective, evidence-
based strategies to reduce the growing burden.
Pioneered in the 1960s,[2] opioid substitution therapy (OST) has 
emerged as the pre-eminent treatment for heroin use disorder. 
The treatment involves prescribing controlled amounts of less 
euphoric long-acting synthetic opioid agonists or partial agonists, 
usually methadone or buprenorphine, to reduce cravings, prevent 
the euphoric effect of use and prevent withdrawal symptoms.[3] Being 
long-acting, the agonists can be dosed once daily, thus eliminating 
the need for multiple daily heroin doses. The intervention stabilises 
users’ drug-using lifestyle, reducing criminal and other high-risk 
behaviour, including needle sharing and promiscuity that predispose 
to HIV and other diseases, and improving adherence to antiretroviral 
treatment for those living with HIV.[4] Much of the evidence for OST’s 
effectiveness, however, has been generated in developed countries 
where such programmes are well-established components of HIV 
prevention and drug treatment strategies. Although sub-Saharan 
Africa accounts for 71% of the global HIV population[5] and an 
estimated 1 778 500 injectable drug users[6] (IDUs), only five of the 
45 countries in the region have OST programmes accessible to the 
general public.[7] There is a need for evidence regarding outcomes 
of these programmes in the South African (SA) context in order to 
strengthen the case for scaling up of services.
The objective of this study was to report on the first, and at the 
time of submission of this article the only, public-funded OST pilot 
programme for heroin users in SA. No robust population-based 
data on the extent of the heroin use problem in SA are available, 
but there were an estimated 12 000 - 18 000 users in Cape Town in 
2004, 23% of whom were IDUs.[8] The use of heroin in Cape Town 
as the primary substance of abuse among participants presenting 
for substance treatment increased from 2% in early 1998 to 12.7% 
in 2014.[9]
The treatment of drug addictions in SA is overseen by the 
Department of Social Development (DSD), with support services 
provided by medical practitioners, psychologists and trained drug 
counsellors. Many non-profit drug rehabilitation centres operate 
in- or outpatient drug rehabilitation services, generally consisting 
of an initial intensive phase followed by continuing care thereafter. 
With funding from the DSD, this pilot OST project was initiated 
in 2013 at Sultan Bahu Rehabilitation Centre (SBRC), a non-
governmental organisation in Mitchell’s Plain, Cape Town. Although 
the programme has treated 168 people in its first 2 years, the demand 
for the service is much greater. Given the high cost of Suboxone 
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(Reckitt Benckiser), the opiate analogue used, objective evidence 
of the programme’s effectiveness will be a prerequisite to changing 
government service planning models.
Since addiction is a chronic condition and extended treatment 
has the best outcomes, the retention rate of participants in OST is 
often a key indicator of the effectiveness of such programmes.[10] 
We compared retention time and response to treatment (measured 
through duration until first use of heroin and number of positive 
tests during the treatment period) for heroin users receiving OST plus 
routine treatment and those receiving standard care only at SBRC 
during 2014.
Methods
Study design and population
This naturalistic retrospective study was approved by the Stellenbosch 
University Health Research Ethics Committee (ref. no. S15/02/031) 
and conducted according to locally and internationally accepted 
ethical guidelines. Records of all participants in the rehabilitation 
programme at SBRC from 1 January to 31 December 2014 were 
reviewed. All participants received the centre’s standard care, 
which includes an intensive initial day programme based on the 
Matrix Model,[11] followed by an aftercare phase. The treatment 
(OST) group was additionally offered a fixed-dose combination 
of buprenorphine and naloxone (4:1) (the opiate analogue) in the 
12-week clinician-monitored programme. The addition of naloxone 
is designed to prevent diversion and misuse of buprenorphine as 
it would precipitate opiate withdrawal if injected but not when 
ingested, because naloxone is poorly absorbed sublingually. 
Participants were accepted into the OST programme after detailed 
assessment by a multidisciplinary treatment team in accordance 
with local and international guidelines for psychosocially assisted 
pharmacological treatment of opioid dependence. The general goal 
of the investigation is to evaluate the participants’ current and/or 
historical social, medical, psychological and legal profiles to aid in 
assessing motivation and treatment goals in order to formulate an 
effective treatment plan.
Data collection and analysis
Data were obtained from clinical case notes kept by the treating 
facility, which comprised an initial extensive clerking and records of 
positive urine tests and episodes of self-reported use. Prescriptions of 
the opiate analogue as well as dispensing information were recorded 
separately. Retention in the programme was measured from time of 
enrolment to the end of the programme or drop out. Also recorded 
were the number of urine samples provided, total number of 
positive tests or self-reported use events, and dates of first positive/
negative tests. General demographic data including sex, race, highest 
educational level attained and debut of substance abuse were also 
collected, as well as voluntary data on HIV status including date of 
last testing where available.
Data were summarised as means (standard deviations (SDs)) and 
medians (25th - 75th percentiles or range) for continuous variables 
and as counts and percentages for categorical variables. Distribution 
of traits between the two treatment groups was assessed using t- 
and χ2 tests for quantitative and qualitative traits, respectively. All 
statistical analyses were performed using SPSS statistical software 
(version 23, IBM Corp., USA) and the level of statistical significance 
was set at p<0.05.
Results
Population demographics
The analysis excluded 33 records with missing core data and 
those from participants on a self-funded OST programme. Of the 
135 analy sable records, 68 (50.4%) were from participants receiving 
standard care only and 67 (49.6%) from those also receiving OST 
(Table 1). All participants were non-injecting users. The mean (SD) 
age was 28.5 (6.5) years, there were more males (91.1%) than females, 
and the majority were single (74.8%) and unemployed (96.3%). The 
Table 1. Summary of demographic data
Variable OST + standard care (n=67) Standard care (n=68) Total (N=135) p-value
Age (yr), mean (SD) 28.7 (6.8) 28.3 (6.4) 28.5 (6.5) 0.700
Gender (male), n (%) 60 (89.6) 63 (92.6) 123 (91.1) 0.742
Substance use debut age (yr), mean (SD) 15.3 (5.0) 15.3 (3.2) 15.3 (4.2) 0.978
Marital status, n (%) 0.229
Single 52 (77.6) 49 (72.1) 101 (74.8)
Married 8 (11.9) 15 (22.1) 23 (17.0)
Divorced 5 (7.5) 4 (5.9) 9 (6.7)
Widowed 2 (3.0) 0 (0) 2 (1.5)
Highest level of education, n (%) 0.915
Primary school 15 (22.4) 14 (20.6) 29 (21.5) 
High school 52 (77.6) 54 (79.4) 106 (78.5)
Employment, n (%) 0.024
Employed 0 (0) 5 (7.4) 5 (3.7)
Unemployed 67 (100) 63 (92.6) 130 (96.3)
HIV status, n (%) 0.573
Known 58 (86.6) 61 (89.7) 119 (88.1)
Unknown 9 (13.4) 7 (10.3) 16 (11.9)
Gang affiliation, n (%) 0.017
None 51 (76.1) 54 (79.4) 105 (77.7)
Past 7 (10.4) 0 (0) 7 (5.2)
Current 9 (13.4) 14 (20.6) 23 (17.1)
Previous arrests, n (%) 58 (86.6) 53 (77.9) 111 (82.2) 0.190
OST = opioid substitution treatment; SD = standard deviation.
541       June 2017, Vol. 107, No. 6
RESEARCH
highest level of education attained was high school (grades 10 - 12) 
for the majority (78.5%), and this was similar in both groups.
An overwhelming majority of the participants (82.2%) had been 
arrested previously, and 17.1% admitted to current gang affiliation. 
Of the participants, 119 knew their HIV status, and 37.8% had been 
tested within the past year.
The mean debut age for use of illicit substances was 15.3 years (range 
8 - 36 years) and 74 participants (54.8%) reported current polydrug 
use, with the drugs most likely to be used together with heroin being 
methamphetamine (90.5%) and cannabis (39.2%) (Table 2).
Main outcomes
As shown in Table 3, significantly more participants in the OST 
group (65.7%) than controls (44.1%) completed treatment (p=0.019). 
Among the non-completers, the retention rate was higher among 
OST participants than in the standard care group (48.2 v. 30.1 days; 
p=0.001). Participants in the OST group had a non-significant 2 days 
longer median duration to first positive drug test or self-reported use. 
The proportion of participants testing positive was higher in the OST 
group (80.6%) than in the standard care group (61.8%), although 
the former were tested nearly three times (18.3 v. 6.6 times) more. 
Consequently, the positive rate (proportion of positive tests) was 
substantially lower in the OST group (16.8%) than in the standard 
care group (23.3%). The dose of the opiate analogue prescribed in the 
OST group ranged from 2 mg to 16 mg (median 4 mg).
Discussion
The study evaluated the performance of SBRC, the first public-funded 
opioid substitution programme in SA, by comparing retention time 
and response to treatment with that of standard care. While the two 
programmes did not differ with regard to duration of abstinence from 
illicit opiate use during rehabilitation, we found that individuals in 
the OST group remained in treatment significantly longer and were 
more likely to complete the programme.
The proportion of participants completing treatment was 
significantly higher (65.7%) in the OST programme than in standard 
care (44.1%). Retention rates in treatment reported in the literature 
vary widely, but it is generally estimated that >50% of patients leave or 
are withdrawn in the first 3 weeks of treatment.[12-14] After 6 months 
of treatment, one study reported retention of 79%,[15] but others 
noted much lower rates of 58%,[16] 46%[17] and 27%.[18] In another 
study, an average of only 44% of buprenorphine clients spent at 
least 3 weeks in an Australian treatment facility.[19] The only other 
evaluation of an OST programme in Africa reported a retention 
rate of 57% over 2 years,[20] although it utilised methadone, which 
differs from buprenorphine with regard to retention.[17] The rate 
for the OST group in our study was therefore relatively high. Even 
among participants who did not complete treatment, those in the 
OST programme remained on average 18 days longer (p=0.001) 
than in the standard group. These findings concur with previous 
reports providing evidence of improved retention rates in OST-based 
rehabilitation programmes.[10]
Response to treatment, denoted by a lower proportion of posi tive 
urine tests, was significantly higher in the OST group. However, 
abstinence from illicit opiates in this group was very low, as shown 
by the exceptionally high proportion of participants (80.6%) 
testing positive compared with other longer-term treatment pro-
grammes. [21-22] While this may reflect international experience that 
longer periods than the SBRC’s 12-week programme are necessary 
for higher abstinence, a possible reason for the low rate could be the 
high rate (54.8%) of concomitant use of other potentially destabilis-
ing drugs, which often leads to impulsive use of heroin during reha-
bilitation.[17] In addition, so that more participants could be included 
in a setting where funding was limited, a lower dose of the opiate 
analogue was used (median 4 mg) than that required to suppress 
illicit opioid use. While any dose above 2 mg retains participants in 
treatment, at least 16 mg is necessary to suppress illicit opioid use.[23]
An encouraging finding was that the vast majority (88.1%) of the 
participants knew their HIV status, and more than a third had been 
tested within the past year. Similar positive findings were highlighted 
by South African Community Epidemiology Network on Drug Use 
(SACENDU) data[9] and may reflect successes made in community 
education pertaining to opioid use disorder as well as provision of 
access to confidential testing facilities. This is significant, as this 
population is at increased risk of contracting viral illness through 
high-risk behaviours such as unsafe sexual practices.
Study limitations
This study was limited by its retrospective nature, which precluded 
uniformity in terms of dosing, frequency of urine tests and client 
selection and restricted the range of variables assessed. The use 
of doses lower than those considered necessary to suppress illicit 
opioid use further limits the generalisability of the results. Future 
Table 2. Comorbid substance use (N=74)
Substance used* n (%)
Cannabis only 4 (5.4)
Methamphetamine only 36 (48.6)
Cannabis + any other 25 (33.8)
Methamphetamine + any other 31 (41.9)
Any two drugs 19 (25.7)
Any three drugs 13 (17.6)
*Substance used in addition to heroin.
Table 3. Main outcomes assessed
Outcome OST + standard care Standard care Total p-value
Completion rate, n (%) 44 (65.7) 30 (44.1) 74 (54.8) 0.019
Mean retention in non-completers (d), mean (SD) 48.2 (20.7) 30.1 (11.4) 36.9 (17.8) 0.001
Number of missed appointments, median (IQR) 4.0 (2.0 - 10.0) 4.0 (1.0 - 10.8) 4.0 (1.0 - 10.8) 0.755
Did not miss any appointments, n (%) 11 (16.4) 13 (19.1) 24 (17.8) 0.853
Days to first positive test, median (IQR) 5 (0 - 42) 3 (0 - 41) 3.5 (1.0 -14.8) 0.783
Participants testing positive, n (%) 54 (80.6) 42 (61.8) 96 (71.1) 0.022
Number of tests, mean (SD) 18.3 (7.4) 6.6 (4.0) 12.4 (8.3) 0.001
Positive rate (%) 16.8 23.3 18.6 n/a
Opiate analogue (Suboxone) dose (mg), median (range) 4 (2 - 16) n/a n/a n/a
OST = opioid substitution treatment; SD = standard deviation; IQR = interquartile range; n/a = not applicable.
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prospective studies should include further outcome measures such 
as relapse rate, mortality, criminality and client quality of life, in 
addition to addressing community and individual factors such as 
participant motivation that are likely to influence retention and 
interact with other outcome measures. Future studies should also 
consider increasing the dose of the opiate analogue to yield reliable 
abstinence data.
Conclusions
The results demonstrate a modest success of this pilot programme in 
terms of completion and retention rates and should argue for a move 
to increase availability of and accessibility to OSTs for management 
of opioid use disorder. This and future local programmes should 
consider extending treatment duration, as longer treatment is often 
required for long-term recovery from opioid addiction.[24] Future 
studies should evaluate performance of these extended programmes, 
and include the wider and more robust outcomes mentioned 
earlier, together with additional measures such as more intensive 
psychosocial support with possible penalties for early dropouts. 
The design of such studies should also allow for a more systematic 
collection of data where variables, such as frequency of urine tests, 
are uniform and consistent to allow better analysis, interpretation and 
utility for evidence-based quality improvement. More investments in 
financial and human resources will be needed to address comorbid 
drug use, gang affiliation and skilling participants to enhance 
prospects for gainful occupation. To improve retention, consideration 
can also be given to inclusion of employment assistance, as some 
authors have suggested.[25]
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